Vol 51, No 3 (2013)
Original paper
Submitted: 2013-05-14
Accepted: 2013-10-07
Published online: 2013-11-07
Get Citation

ACE and ACE2 expression in normal and malignant skin lesions

Jedrzej Grzegrzolka, Katarzyna Swiatko, Bartosz Pula, Aleksandra Zamirska, Mateusz Olbromski, Andrzej Bieniek, Jacek Szepietowski, Janusz Rys, Piotr Dziegiel, Marzenna Podhorska-Okolow
DOI: 10.5603/FHC.2013.0033
·
Folia Histochem Cytobiol 2013;51(3):232-238.
Vol 51, No 3 (2013)
ORIGINAL PAPERS
Submitted: 2013-05-14
Accepted: 2013-10-07
Published online: 2013-11-07

Abstract

The renin-angiotensin system (RAS) is known mainly as a regulator of cardiovascular homeostasis. However, it has also been shown to mediate processes such as proliferation, apoptosis, angiogenesis, and carcinogenesis. Nonmelanoma skin cancers (NMSC) — including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) — are among the most common cancers. The aim of the present study was to determine the immunohistochemical expression of angiotensin-converting enzyme (ACE), angiotensin-converting enzyme 2 (ACE2), and Ki-67 antigen in archival samples of normal skin, actinic keratosis, and malignant skin lesions. Cytoplasmic-nuclear ACE immunoreactivity was observed in 99% of examined cases of both normal skin and cancers. Significantly higher ACE immunoreactivity occurred in normal skin, as compared with BCC and SCC (p < 0.01, p < 0.0001, respectively). Additionally, ACE immunoreactivity was also significantly higher in BCC, compared with SCC (p < 0.05). ACE2 immunoreactivity was noted in basal epidermal layers and in sebaceous gland cells in normal skin, though not in NMSC. These novel observations suggest that ACE and skin RAS may be involved in the pathogenesis of malignant skin lesions.

Abstract

The renin-angiotensin system (RAS) is known mainly as a regulator of cardiovascular homeostasis. However, it has also been shown to mediate processes such as proliferation, apoptosis, angiogenesis, and carcinogenesis. Nonmelanoma skin cancers (NMSC) — including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) — are among the most common cancers. The aim of the present study was to determine the immunohistochemical expression of angiotensin-converting enzyme (ACE), angiotensin-converting enzyme 2 (ACE2), and Ki-67 antigen in archival samples of normal skin, actinic keratosis, and malignant skin lesions. Cytoplasmic-nuclear ACE immunoreactivity was observed in 99% of examined cases of both normal skin and cancers. Significantly higher ACE immunoreactivity occurred in normal skin, as compared with BCC and SCC (p < 0.01, p < 0.0001, respectively). Additionally, ACE immunoreactivity was also significantly higher in BCC, compared with SCC (p < 0.05). ACE2 immunoreactivity was noted in basal epidermal layers and in sebaceous gland cells in normal skin, though not in NMSC. These novel observations suggest that ACE and skin RAS may be involved in the pathogenesis of malignant skin lesions.

Get Citation

Keywords

skin cancer; BCC; SCC; actinic keratosis; ACE; ACE2; immunohistochemistry

About this article
Title

ACE and ACE2 expression in normal and malignant skin lesions

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 51, No 3 (2013)

Article type

Original paper

Pages

232-238

Published online

2013-11-07

DOI

10.5603/FHC.2013.0033

Bibliographic record

Folia Histochem Cytobiol 2013;51(3):232-238.

Keywords

skin cancer
BCC
SCC
actinic keratosis
ACE
ACE2
immunohistochemistry

Authors

Jedrzej Grzegrzolka
Katarzyna Swiatko
Bartosz Pula
Aleksandra Zamirska
Mateusz Olbromski
Andrzej Bieniek
Jacek Szepietowski
Janusz Rys
Piotr Dziegiel
Marzenna Podhorska-Okolow

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl